← Back to Clinical Trials
Recruiting NCT07107568

NCT07107568 Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07107568
Status Recruiting
Phase
Sponsor Medical University Innsbruck
Condition Aortic Valve Stenosis and Insufficiency
Study Type INTERVENTIONAL
Enrollment 700 participants
Start Date 2025-08-14
Primary Completion 2029-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Standard Invasive Coronary AngiographyPCD-CT-Guided Diagnostic Strategy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 700 participants in total. It began in 2025-08-14 with a primary completion date of 2029-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to determine whether a non-invasive coronary assessment strategy using photon-counting detector computed tomography (PCD-CT) is non-inferior to invasive coronary angiography (ICA) for evaluating coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Severe aortic valve stenosis and indication for intervention according to current European Society of Cardiology (ESC) guidelines * TAVR candidate * Written informed consent Exclusion Criteria: * Cardiogenic shock at presentation (e.g., emergency indication for TAVR) * Severe renal impairment with an estimated glomerular filtration rate of \<30 mL/min/1.73 m² * Life expectancy \<1 year due to other severe non-cardiac disease (e.g., malignancy) * Pregnancy

Contact & Investigator

Central Contact

Sebastian J Reinstadler, MD, PhD

✉ sebastian.reinstadler@tirol-kliniken.at

📞 +43 512 504 25665

Principal Investigator

Sebastian J Reinstadler, MD, PhD

PRINCIPAL INVESTIGATOR

Medical University Innsbruck

Frequently Asked Questions

Who can join the NCT07107568 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Valve Stenosis and Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07107568 currently recruiting?

Yes, NCT07107568 is actively recruiting participants. Contact the research team at sebastian.reinstadler@tirol-kliniken.at for enrollment information.

Where is the NCT07107568 trial being conducted?

This trial is being conducted at Innsbruck, Austria.

Who is sponsoring the NCT07107568 clinical trial?

NCT07107568 is sponsored by Medical University Innsbruck. The principal investigator is Sebastian J Reinstadler, MD, PhD at Medical University Innsbruck. The trial plans to enroll 700 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology